Belantamab Mafodotin Combination Therapy

A Study of Belantamab Mafodotin in Combination With and Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

What will happen during the trial?

The purpose of this study is to find out whether combination treatment with the study drugs belantamab mafodotin, nirogacestat, and pomalidomide is a safe treatment for people who have relapsed or refractory multiple myeloma. The researchers will test different doses of belantamab mafodotin to find the safest dose to give with nirogacestat and pomalidomide. The researchers also want to find out whether belantamab mafodotin plus nirogacestat and pomalidomide is an effective treatment for this type of bone marrow cancer, and the researchers will do tests that show whether the study treatment slows or stops the growth of cancer.

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
30 patients (estimated)
Sponsors
Memorial Sloan-Kettering Cancer Center
Tags
Antibody Drug Conjugate (ADC), Gamma-Secretase Inhibitor, B-Cell Maturation Antigen (BCMA)
Trial Type
Treatment
Last Update
2 weeks ago
SparkCures ID
1314
NCT Identifier
NCT05556798

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.